The first comparison of PROs with axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, to SOC as second-line treatment (Tx) in relapsed/refractory (R/R) LBCL in the pivotal Phase 3 ZUMA-7 project.
According to ZUMA-7, the first randomized, international, multicenter Phase 3 study comparing axi-cel to SOC in second-line R/R LBCL, axi-cel treatment results in a clinically significant improvement in QoL at D100 when compared to SOC as determined by many recognized PRO tools. In the SOC arm, in particular, score comparisons at later timepoints call for cautious interpretation because attrition brought on by EFS events may have selected participants with the greatest results. The statistics also point to a quicker return to pretreatment quality of life with axi-cel than with SOC. Treatment options for second-line R/R LBCL should be influenced by axi-better cel's clinical results and patient experience compared to SOC.
Learn more about ZUMA-7 here:-
brainly.com/question/23849777
#SPJ4
Answer: Bleach
Explanation: Trump
*This is a joke*
Answer:
J11111111111111111111111
Step by step explanation:
The dosage or the dosage interval may need to be reduced
